Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 4/20 | 0.56 |
| ▸ | SRC | P12931 | 6/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.41 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.41 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495758 | 0.91 | HPGDS (0.54) | HPGDSSRCROCK2F10F2 | |
| SCHEMBL16495485 | 0.91 | SRC (0.50) | HPGDSSRCF10HDAC1HDAC6 | |
| SCHEMBL16496076 | 0.88 | HPGDS (0.54) | HPGDSSRCHDAC1HDAC6TPSAB1 | |
| SCHEMBL16495584 | 0.83 | SRC (0.53) | HPGDSSRCHDAC1HDAC6 | |
| SCHEMBL16495666 | 0.81 | HPGDS (0.55) | HPGDSSRCHDAC1HDAC6 | |
| SCHEMBL16495915 | 0.80 | SRC (0.51) | HPGDSSRCHDAC1HDAC6TPSAB1 | |
| SCHEMBL16496138 | 0.79 | SRC (0.49) | HPGDSSRCF10F2HDAC1 | |
| SCHEMBL16496171 | 0.79 | HPGDS (0.53) | HPGDSSRCHDAC1HDAC6ALDH1A1 | |
| SCHEMBL16495728 | 0.77 | HPGDS (0.59) | HPGDSROCK2MAPTKDM4ETP53 | |
| SCHEMBL16495829 | 0.75 | HPGDS (0.57) | HPGDSROCK2TP53ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HPGDS 1073/4885SRC 4371/4885ROCK2 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.